Kintor Pyrilutamide KX-826 Phase 3 Results Shared

The world’s current furthest developed drug for androgenic alopecia prior to approval, Kintor’s pyrilutamide aka KX-826, has completed its phase 3 trial for men in China. A non-detailed explanation of the trial’s data was sent out by Kintor Pharmaceutical on November 27, 2023. In short, pyrilutamide showed overall safety in the trial with no serious adverse events reported, the drug also showed an increase in target area hair count (TAHC) in the treatment group compared to their baseline numbers, and it also showed improvement in TAHC over placebo during all treatment visits of the trial, though they were not statistically significant. Therefore, overall KX-826 did not show a statistically significant improvement in TAHC compared to placebo. The future of pyrilutamide for AGA is now uncertain.